Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Prospective Study on the Efficacy and Safety of Peginterferon Alfa-2b Combined With Nucleos(t)Ide Analogues in Patients With Compensated HBV-Related Liver Cirrhosis

NCT07183293 is registered in ClinicalTrials.gov with Xiamen Humanity Hospital as lead sponsor.

NCT NCT07183293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Prospective Study on the Efficacy and Safety of Peginterferon Alfa-2b Combined With Nucleos(t)Ide Analogues in Patients With Compensated HBV-Related Liver Cirrhosis
Lead sponsor
Xiamen Humanity Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
September 30, 2031
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hbv-related liver cirrhosis